Aastrom Biosciences, which develops stem cell therapies, said Tuesday it has been granted a U.S. patent for its investigational expanded autologous cell therapy.
The Ann Arbor, Mich., company said the patent supports the basis for a cellular therapy derived from its technology. Aastrom expands cells derived from patient bone marrow to help treat cardiovascular diseases like critical limb ischemia and dilated cardiomyopathy.
"The patent establishes the novelty of our cell populations which we believe produce a greater combined therapeutic benefit than purified cell populations or freshly isolated bone marrow cells," CEO Tim Mayleben said in a statement.
Shares of Aastrom Biosciences Inc., climbed 3 cents to $3.11 in Tuesday morning trading.